Copenhagen University Hospital–Herlev and Gentofte led a nationwide registry study that the authors claim shows a "pattern ...

Subgroup analyses from one of the agent's pivotal trials showed that 29.5% of adolescents receiving icotrokinra achieved PASI ...

Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing ...

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...

Results of a meta-analysis showed that all biologic agents were superior to placebo for improving short-term outcomes in moderate to severe plaque psoriasis.

HealthDay News — Severe psoriasis, nail pitting, and the use of retinoids were identified as possible risk factors for development of psoriatic arthritis (PsA) among patients with psoriasis, according ...

Please provide your email address to receive an email when new articles are posted on . The proportion of deucravacitinib-treated patients that reported no quality-of-life impact increased from 0% at ...

Patients with moderate to severe psoriasis may benefit from weekend cyclosporine treatment (WCT) as a maintenance therapy, according to one study. The use of weekend cyclosporine treatment (WCT) was ...

A 46-year-old man presents for his first dermatology consultation for worsening symptoms of plaque psoriasis and recent-onset joint pain. He reports “painful aching” and swelling of his finger joints, ...

PSORIASIS is no longer regarded as a single, uniform condition. Once classified primarily by visible lesions or severity, it ...

Otezla (apremilast) is an oral tablet commonly used to treat plaque psoriasis in adults and children. Plaque psoriasis is an inflammatory skin condition that causes itchy, painful patches on the skin.

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...